Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:N-acylpyrrolidine
go back to main search page
Accession:CHEBI:46766 term browser browse the term
Synonyms:related_synonym: N-acylpyrrolidines



show annotations for term's descendants           Sort by:
 
aniracetam term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ces1d carboxylesterase 1D increases hydrolysis ISO CES1 protein results in increased hydrolysis of aniracetam CTD PMID:9300133 NCBI chr19:13,873,490...13,912,035 JBrowse link
G Ces2h carboxylesterase 2H increases hydrolysis ISO CES2 protein results in increased hydrolysis of aniracetam CTD PMID:9300133 NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
JBrowse link
captopril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme multiple interactions
decreases activity
EXP
ISO
Captopril inhibits the reaction [Pregabalin results in increased expression of ACE protein]
Captopril inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACE protein]
Captopril results in decreased activity of ACE protein
CTD PMID:26851370 PMID:31629013 PMID:33007385 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ace2 angiotensin I converting enzyme 2 decreases response to substance
multiple interactions
ISO
EXP
ACE2 gene SNP results in decreased susceptibility to Captopril
Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]
Captopril inhibits the reaction [Pregabalin results in decreased expression of ACE2 protein]
CTD PMID:17473847 PMID:31629013 PMID:33007385 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]
Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
CTD PMID:31181250 PMID:33007385 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Agt angiotensinogen multiple interactions EXP
ISO
Captopril inhibits the reaction [Pregabalin results in decreased expression of AGT protein]
Captopril inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Captopril inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Captopril inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of AGT protein]; Captopril inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of VIM protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]
CTD PMID:28130181 PMID:31181250 PMID:31629013 PMID:33007385 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP
ISO
Captopril inhibits the reaction [Pregabalin results in increased expression of AGTR1 protein]
Captopril inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein]
CTD PMID:28130181 PMID:31629013 PMID:33007385 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Bdkrb2 bradykinin receptor B2 multiple interactions ISO Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein] CTD PMID:28130181 NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
JBrowse link
G Calb1 calbindin 1 multiple interactions ISO Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein] CTD PMID:28130181 NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
JBrowse link
G Car2 carbonic anhydrase 2 multiple interactions ISO Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA] CTD PMID:28130181 NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO Captopril inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] CTD PMID:33007385 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO Captopril inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] CTD PMID:33007385 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Gli1 GLI family zinc finger 1 multiple interactions EXP
ISO
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]
CTD PMID:31181250 NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
JBrowse link
G Gli2 GLI family zinc finger 2 multiple interactions EXP
ISO
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]
CTD PMID:31181250 NCBI chr13:29,946,809...30,163,901
Ensembl chr13:29,946,809...30,163,574
JBrowse link
G Gli3 GLI family zinc finger 3 multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]
CTD PMID:31181250 NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
JBrowse link
G Lepr leptin receptor multiple interactions
affects response to substance
ISO Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein]; Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein]; Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of VDR protein]
LEPR protein affects the susceptibility to Captopril
CTD PMID:28130181 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Mas1 MAS1 proto-oncogene, G protein-coupled receptor multiple interactions EXP
ISO
Captopril inhibits the reaction [Pregabalin results in decreased expression of MAS1 protein]
Captopril inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein]
CTD PMID:31629013 PMID:33007385 NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA] CTD PMID:28130181 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Nppb natriuretic peptide B multiple interactions EXP Captopril inhibits the reaction [Pregabalin results in increased expression of NPPB protein] CTD PMID:31629013 NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions EXP Captopril inhibits the reaction [Pregabalin results in decreased expression of PRKACA protein] CTD PMID:31629013 NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
JBrowse link
G Ptch1 patched 1 multiple interactions EXP
ISO
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]
CTD PMID:31181250 NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
JBrowse link
G Pth parathyroid hormone multiple interactions ISO Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein] CTD PMID:28130181 NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA] CTD PMID:28130181 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Shh sonic hedgehog signaling molecule multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]
CTD PMID:31181250 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
JBrowse link
G Smo smoothened, frizzled class receptor multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]
CTD PMID:31181250 NCBI chr 4:58,344,101...58,372,828
Ensembl chr 4:58,343,529...58,373,829
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO Captopril promotes the reaction [LEPR protein affects the expression of VDR protein] CTD PMID:28130181 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA] CTD PMID:28130181 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vim vimentin multiple interactions ISO Captopril inhibits the reaction [AGT protein results in increased expression of VIM protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] CTD PMID:33007385 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
ledipasvir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 affects binding ISO ledipasvir binds to ABCG2 protein CTD PMID:33954893 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Klrc1 killer cell lectin like receptor C1 decreases expression ISO ledipasvir co-treated with sofosbuvir decreases expression of NCR1 protein in natural killer cells RGD PMID:31218578 RGD:40400920 NCBI chr 4:163,142,142...163,152,425
Ensembl chr 4:163,147,189...163,152,425
JBrowse link
G Ncr1 natural cytotoxicity triggering receptor 1 affects expression ISO ledipasvir co-treated sofosbuvir with affects expression of NCR1 protein in natural killer cells RGD PMID:31218578 RGD:40400920 NCBI chr 1:69,614,744...69,622,570 JBrowse link
PF-956980 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA] CTD PMID:23968543 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein] CTD PMID:23968543 NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536
JBrowse link
G Osm oncostatin M multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:23968543 NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:23968543 NCBI chr 9:49,419,561...49,459,969 JBrowse link
PHA-665752 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein] CTD PMID:22040890 PMID:25002221 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein CTD PMID:20661229 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein
Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
CTD PMID:20661229 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein] CTD PMID:22040890 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Egfr epidermal growth factor receptor decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
CTD PMID:21266357 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] CTD PMID:20661229 PMID:21812414 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
increases mutagenesis
decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
CTD PMID:20661229 PMID:21106725 PMID:21266357 PMID:21812414 PMID:25002221 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
CTD PMID:21266357 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
increases response to substance
increases expression
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
CTD PMID:21266357 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein CTD PMID:20661229 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19812
    chemical entity 19812
      atom 19811
        nonmetal atom 19698
          nitrogen atom 18774
            nitrogen molecular entity 18774
              amide 17590
                N-acylpyrrolidine 47
                  (1S)-2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine 0
                  (1S)-2-[(2S,5R)-2-(aminomethyl)-5-prop-1-yn-1-ylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine 0
                  (2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine 0
                  (2S)-3-(3-pyridyl)propyl 1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine-2-carboxylate 0
                  (2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-(\{(3R)-1-[(1Z)-ethanimidoyl]pyrrolidin-3-yl\}oxy)phenyl]propanoic acid 0
                  (2S)-3-methyl-2-((2R,3S)-3-[(methylsulfonyl)amino]-1-\{[2-(pyrrolidin-1-ylmethyl)-1,3-oxazol-4-yl]carbonyl\}pyrrolidin-2-yl)butanoic acid 0
                  (2S,3S)-3-\{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl\}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine 0
                  (2S,4R)-1-acetyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-(benzothiazol-2-ylcarbonyl)butyl]-4-hydroxypyrrolidine-2-carboxamide 0
                  (2S,4S,5R)-1-(4-tert-butylbenzoyl)-2-isobutyl-5-(1,3-thiazol-2-yl)pyrrolidine-2,4-dicarboxylic acid 0
                  (2S,4S,5R)-2-isobutyl-5-(2-thienyl)-1-[4-(trifluoromethyl)benzoyl]pyrrolidine-2,4-dicarboxylic acid 0
                  (3S)-1-[(E)-amino(imino)methyl]-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)piperidine-3-carboxamide 0
                  (3S)-1-\{[(3,5-dimethylisoxazol-4-yl)amino]carbonyl\}-4,4-dimethylpyrrolidin-3-yl \{(1S)-1-[1-hydroxy-2-oxo-2-\{[(1R)-1-phenylethyl]amino\}ethyl]pentyl\}carbamate 0
                  (4S)-1-[(4-butoxyphenyl)sulfonyl]-N-hydroxy-4-[(methylsulfonyl)amino]-D-prolinamide 0
                  (4S)-N-hydroxy-4-(methoxyamino)-1-[(4-methoxyphenyl)sulfonyl]-D-prolinamide 0
                  1-(3-mercapto-2-methylpropionyl)pyrrolidine-2-carboxylic acid 0
                  1-[(2E,4E)-2,4-decadienoyl]pyrrolidine 0
                  1-[(2E,4E)-2,4-dodecadienoyl]pyrrolidine 0
                  1-[(2E,4E,6E)-2,4,6-dodecatrienoyl]pyrrolidine 0
                  1-[(3aR)-5-\{[3-(2,4-difluorophenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl]carbonyl\}-6-methoxy-3aH-pyrrolo[2,3-b]pyridin-3-yl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]-2-oxoethanone 0
                  1-[2-[3-(1-propan-2-ylsulfonylazetidin-3-yl)-1,2,4-oxadiazol-5-yl]pyrrolidin-1-yl]ethanone 0
                  1-[3,3-dimethyl-2-(2-2-methylaminopropionylamino)butyryl]-4-phenoxypyrrolidine-2-[N-(1,2,3,4-tetrahydronaphthalen-1-yl)]carboxamide 0
                  1-\{[1-(2-amino-3-phenylpropionyl)pyrrolidine-2-carbonyl]amino\}-2-(3-cyanophenyl)ethaneboronic acid 0
                  1-propanoylproline 0
                  2-[4-(\{(S)-1-[((S)-2-\{[(RS)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl\}pyrrolidin-1-yl)carbonyl]-2-methylpropyl\}aminocarbonyl)benzoylamino]acetic acid 0
                  2-[4-(\{2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl\}amino)-4-methylpiperidin-1-yl]isonicotinic acid 0
                  2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one 0
                  4-\{[(2R,5S)-5-\{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl\}pyrrolidin-2-yl]methoxy\}-3-tert-butylbenzoic acid 0
                  4-\{[(E)-amino(imino)methyl]amino\}-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)butanamide 0
                  6-(4-\{(1S,2S)-2-amino-1-[(dimethylamino)carbonyl]-3-[(3S)-3-fluoropyrrolidin-1-yl]-3-oxopropyl\}phenyl)-1H-[1,2,4]triazolo[1,5-a]pyridin-4-ium 0
                  LSM-1512 0
                  N(2)-[(benzyloxy)carbonyl]-N(1)-((3R)-1-\{N-[(benzyloxy)carbonyl]-L-leucyl\}-4-oxopyrrolidin-3-yl)-L-leucinamide 0
                  N-(14-Methylhexadecanoyl)pyrrolidine 0
                  N-(\{(2S)-1-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-yl\}methyl)benzamide 0
                  N-(trans-4-\{(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl\}cyclohexyl)-N-methylacetamide 0
                  N-Hexadecanoylpyrrolidine 0
                  N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                  N-[4-(D-prolinosulfonyl)benzoyl]-L-glutamic acid 0
                  N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide 0
                  N-\{(2S,3R)-2-[(1S)-1-formyl-2-methylpropyl]-1-[(2E)-4-piperidin-1-ylbut-2-enoyl]pyrrolidin-3-yl\}methanesulfonamide 0
                  N-acetyl-D-proline 0
                  N-acetyl-L-proline + 0
                  N-acetyltryptophyl-N(1)-\{3-[1-(N-acetyltryptophylvalyl)pyrrolidin-2-yl]-1-benzyl-2,3-dihydroxypropyl\}valinamide 0
                  N-benzyloxycarbonyl-L-prolyl-L-prolinal 0
                  PF-956980 4
                  PHA-665752 12
                  Variotin 0
                  [(R)-1-L-prolylpyrrolidin-2-yl]boronic acid 0
                  aniracetam 2
                  captopril + 26
                  dextromoramide 0
                  elbasvir + 0
                  ledipasvir + 3
                  malyngamide B 0
                  methyl 4-\{[(\{[(2R,5S)-5-\{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl\}pyrrolidin-2-yl]methyl\}amino)carbonyl]amino\}benzoate 0
                  tert-butyl \{1-[2-(1-formylpropyl)-3-methanesulfonylaminopyrrolidine-1-carbonyl]-2-methylpropyl\}carbamate 0
                  velpatasvir + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19812
    subatomic particle 19811
      composite particle 19811
        hadron 19811
          baryon 19811
            nucleon 19811
              atomic nucleus 19811
                atom 19811
                  main group element atom 19710
                    p-block element atom 19710
                      carbon group element atom 19631
                        carbon atom 19621
                          organic molecular entity 19621
                            organic molecule 19562
                              organic cyclic compound 19356
                                organic heterocyclic compound 18596
                                  organic heteromonocyclic compound 17120
                                    pyrrolidines 2265
                                      N-acylpyrrolidine 47
                                        (1S)-2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine 0
                                        (1S)-2-[(2S,5R)-2-(aminomethyl)-5-prop-1-yn-1-ylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine 0
                                        (2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine 0
                                        (2S)-3-(3-pyridyl)propyl 1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine-2-carboxylate 0
                                        (2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-(\{(3R)-1-[(1Z)-ethanimidoyl]pyrrolidin-3-yl\}oxy)phenyl]propanoic acid 0
                                        (2S)-3-methyl-2-((2R,3S)-3-[(methylsulfonyl)amino]-1-\{[2-(pyrrolidin-1-ylmethyl)-1,3-oxazol-4-yl]carbonyl\}pyrrolidin-2-yl)butanoic acid 0
                                        (2S,3S)-3-\{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl\}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine 0
                                        (2S,4R)-1-acetyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-(benzothiazol-2-ylcarbonyl)butyl]-4-hydroxypyrrolidine-2-carboxamide 0
                                        (2S,4S,5R)-1-(4-tert-butylbenzoyl)-2-isobutyl-5-(1,3-thiazol-2-yl)pyrrolidine-2,4-dicarboxylic acid 0
                                        (2S,4S,5R)-2-isobutyl-5-(2-thienyl)-1-[4-(trifluoromethyl)benzoyl]pyrrolidine-2,4-dicarboxylic acid 0
                                        (3S)-1-[(E)-amino(imino)methyl]-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)piperidine-3-carboxamide 0
                                        (3S)-1-\{[(3,5-dimethylisoxazol-4-yl)amino]carbonyl\}-4,4-dimethylpyrrolidin-3-yl \{(1S)-1-[1-hydroxy-2-oxo-2-\{[(1R)-1-phenylethyl]amino\}ethyl]pentyl\}carbamate 0
                                        (4S)-1-[(4-butoxyphenyl)sulfonyl]-N-hydroxy-4-[(methylsulfonyl)amino]-D-prolinamide 0
                                        (4S)-N-hydroxy-4-(methoxyamino)-1-[(4-methoxyphenyl)sulfonyl]-D-prolinamide 0
                                        1-(3-mercapto-2-methylpropionyl)pyrrolidine-2-carboxylic acid 0
                                        1-[(2E,4E)-2,4-decadienoyl]pyrrolidine 0
                                        1-[(2E,4E)-2,4-dodecadienoyl]pyrrolidine 0
                                        1-[(2E,4E,6E)-2,4,6-dodecatrienoyl]pyrrolidine 0
                                        1-[(3aR)-5-\{[3-(2,4-difluorophenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl]carbonyl\}-6-methoxy-3aH-pyrrolo[2,3-b]pyridin-3-yl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]-2-oxoethanone 0
                                        1-[2-[3-(1-propan-2-ylsulfonylazetidin-3-yl)-1,2,4-oxadiazol-5-yl]pyrrolidin-1-yl]ethanone 0
                                        1-[3,3-dimethyl-2-(2-2-methylaminopropionylamino)butyryl]-4-phenoxypyrrolidine-2-[N-(1,2,3,4-tetrahydronaphthalen-1-yl)]carboxamide 0
                                        1-\{[1-(2-amino-3-phenylpropionyl)pyrrolidine-2-carbonyl]amino\}-2-(3-cyanophenyl)ethaneboronic acid 0
                                        1-propanoylproline 0
                                        2-[4-(\{(S)-1-[((S)-2-\{[(RS)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl\}pyrrolidin-1-yl)carbonyl]-2-methylpropyl\}aminocarbonyl)benzoylamino]acetic acid 0
                                        2-[4-(\{2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl\}amino)-4-methylpiperidin-1-yl]isonicotinic acid 0
                                        2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one 0
                                        4-\{[(2R,5S)-5-\{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl\}pyrrolidin-2-yl]methoxy\}-3-tert-butylbenzoic acid 0
                                        4-\{[(E)-amino(imino)methyl]amino\}-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)butanamide 0
                                        6-(4-\{(1S,2S)-2-amino-1-[(dimethylamino)carbonyl]-3-[(3S)-3-fluoropyrrolidin-1-yl]-3-oxopropyl\}phenyl)-1H-[1,2,4]triazolo[1,5-a]pyridin-4-ium 0
                                        LSM-1512 0
                                        N(2)-[(benzyloxy)carbonyl]-N(1)-((3R)-1-\{N-[(benzyloxy)carbonyl]-L-leucyl\}-4-oxopyrrolidin-3-yl)-L-leucinamide 0
                                        N-(14-Methylhexadecanoyl)pyrrolidine 0
                                        N-(\{(2S)-1-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-yl\}methyl)benzamide 0
                                        N-(trans-4-\{(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl\}cyclohexyl)-N-methylacetamide 0
                                        N-Hexadecanoylpyrrolidine 0
                                        N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                                        N-[4-(D-prolinosulfonyl)benzoyl]-L-glutamic acid 0
                                        N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide 0
                                        N-\{(2S,3R)-2-[(1S)-1-formyl-2-methylpropyl]-1-[(2E)-4-piperidin-1-ylbut-2-enoyl]pyrrolidin-3-yl\}methanesulfonamide 0
                                        N-acetyl-D-proline 0
                                        N-acetyl-L-proline + 0
                                        N-acetyltryptophyl-N(1)-\{3-[1-(N-acetyltryptophylvalyl)pyrrolidin-2-yl]-1-benzyl-2,3-dihydroxypropyl\}valinamide 0
                                        N-benzyloxycarbonyl-L-prolyl-L-prolinal 0
                                        PF-956980 4
                                        PHA-665752 12
                                        Variotin 0
                                        [(R)-1-L-prolylpyrrolidin-2-yl]boronic acid 0
                                        aniracetam 2
                                        captopril + 26
                                        dextromoramide 0
                                        elbasvir + 0
                                        ledipasvir + 3
                                        malyngamide B 0
                                        methyl 4-\{[(\{[(2R,5S)-5-\{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl\}pyrrolidin-2-yl]methyl\}amino)carbonyl]amino\}benzoate 0
                                        tert-butyl \{1-[2-(1-formylpropyl)-3-methanesulfonylaminopyrrolidine-1-carbonyl]-2-methylpropyl\}carbamate 0
                                        velpatasvir + 0
paths to the root